Alnylam

Advancements in RNAi Therapeutics | 2024-2025 Update for Investors in Hospitals and HealthcareRNA interference (RNAi) therapeutics have garnered significant…

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently includes Pfizer and BridgeBio and is…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York…

CNBC’s Angelica Peebles talks to Alnylam CEO Yvonne Greenstreet about the new administration, what to expect in 2025 and the latest on their ATTR-Cardiomyopathy…

Alnylam Pharmaceuticals, Inc., an American company at the forefront of innovation, today received the 2024 Tell Award from Ambassador Niculin Jaeger, Consul General…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth…

Alnylam Pharmaceuticals, Inc. News− Echocardiographic and Cardiac Biomarker Data From the HELIOS-B Study Presented Today Support the Potential of Vutrisiran in…

– Family Health History Road Trip Program Aims to Inspire Conversations About Health History and Empower Families to Take Control of Their Health ––…

Novo Nordisk has struck a $1.2 billion deal to buy Prothena’s ATTR amyloidosis program, which was stalled by the pandemic last year.The deal will see Novo pay $100…